Literature DB >> 15816901

Heart transplantation in a 68-year-old patient with senile systemic amyloidosis.

Uwe Fuchs1, Armin Zittermann, Ole Suhr, Gösta Holmgren, Gero Tenderich, Kazutomo Minami, Reiner Koerfer.   

Abstract

Senile systemic amyloidosis (SSA) results from deposition, predominantly in the heart, of amyloid fibrils derived from wild-type transthyretin (T TR) molecules. Cardiac autopsies indicate that SSA progressively increases in subjects 80 years of age and older. However, only a few cases of patients with SSA and cardiac failure have been recognized by cardiac biopsies during life. Here, we report a case of heart transplantation in a 68-year-old male patient with SSA. After cardiopulmonary resuscitation in October 1998, he underwent complete evaluation. Myocardial biopsies revealed the presence of amyloid deposition. Immunohistochemical staining of the amyloid indicated T TR. Genomic DNA analysis of the T TR exons did not result in any identification of a mutation. In 2001, heart transplantation was performed because progressive heart failure occurred. At the 1-year follow-up, no amyloid deposits were found in the donor heart. At the 2-year follow-up, the patient's physical and mental health was excellent. We conclude that heart transplantation can be an effective treatment in progressive heart failure due to SSA.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15816901     DOI: 10.1111/j.1600-6143.2005.00805.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  8 in total

Review 1.  Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells.

Authors:  Sangho Lee; Young-Sup Yoon
Journal:  Br J Pharmacol       Date:  2013-05       Impact factor: 8.739

2.  Old men and thickened hearts.

Authors:  Simon William Dubrey; Freya Lodge
Journal:  BMJ Case Rep       Date:  2010-05-06

3.  A case of a senile systemic amyloidosis patient presenting with angina pectoris and dilated cardiomyopathy.

Authors:  Gu Hyun Kang; Dong Ryeol Ryu; Pil Sang Song; Young Bin Song; Joo-Yong Hahn; Seung-Hyuck Choi; Hyeon-Cheol Gwon
Journal:  Korean Circ J       Date:  2011-04-30       Impact factor: 3.243

Review 4.  Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.

Authors:  Ilia G Halatchev; Jingsheng Zheng; Jiafu Ou
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

5.  Advances in bone marrow-derived cell therapy: CD31-expressing cells as next generation cardiovascular cell therapy.

Authors:  Sung-Whan Kim; Hyongbum Kim; Young-sup Yoon
Journal:  Regen Med       Date:  2011-05       Impact factor: 3.806

6.  Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population.

Authors:  Urban Hellman; Flora Alarcon; Hans-Erik Lundgren; Ole B Suhr; Catherine Bonaiti-Pellié; Violaine Planté-Bordeneuve
Journal:  Amyloid       Date:  2008-09       Impact factor: 7.141

Review 7.  Transthyretin (TTR) cardiac amyloidosis.

Authors:  Frederick L Ruberg; John L Berk
Journal:  Circulation       Date:  2012-09-04       Impact factor: 29.690

8.  Cardiovascular repair with bone marrow-derived cells.

Authors:  Woan-Sang Kim; Sangho Lee; Young-Sup Yoon
Journal:  Blood Res       Date:  2013-06-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.